Metabolic Disorder Drugs Market Global Briefing 2018 Including: Anti Metabolites, Anti Diabetics, Anti Thyroid Drugs, And Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).Covering: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG
North America was the largest region in the metabolic disorder drugs market in 2016, accounting for around 53% market share. This was mainly due to high prevalence of metabolic syndrome (combination of metabolic diseases including type-2 diabetes) in the USA. Western Europe was the second largest region accounting for around 16% market share. Asia Pacific was the third largest region accounting for around 15% market share.
Metabolic Disorder Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global metabolic disorder drugs sector.
Reasons to Purchase
- Fully updated for 2018.
- Identify growth segments and opportunities.
- Facilitate decision making on the basis of historic and forecast data and understand the drivers and restraints on the market.
- Develop strategies based on likely future developments.
- Gain a global perspective on the development of the market.
Metabolic Disorder Drugs Market Global Briefing 2018 from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the metabolic disorder drugs market revenues, covering both the historic growth of the market and forecasting the future.
Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in the last three years are identified.
The trends and strategies section highlights the likely future developments in the metabolic disorder drugs market and suggests approaches. Scope
Markets Covered: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).
Companies Mentioned: Sanofi S.A., Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson, Merck & Co., Abbott Laboratories Inc., Boehringer Ingelheim GmbH, AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., Bayer AG
Geographic scope: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, market share of competitors, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.